Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process
Open Access
- 29 September 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 63 (4), 1357-1367
- https://doi.org/10.1002/hep.28256
Abstract
Primary sclerosing cholangitis (PSC) is a rare, but serious, cholestatic disease for which, to date, no effective therapy exists to halt disease progression toward end‐stage liver disease. Clinical trial design to study drugs that improve prognosis is hampered by the relatively low event rate of clinically relevant endpoints. To overcome this shortcoming, there is an urgent need to identify appropriate surrogate endpoints. At present, there are no established surrogate endpoints. This article provides a critical review and describes the results of a consensus process initiated by the International PSC Study Group to delineate appropriate candidate surrogate endpoints at present for clinical trials in this frequently dismal disease. The consensus process resulted in a shortlist of five candidates as surrogate endpoints for measuring disease progression: alkaline phosphatase (ALP); transient elastography (TE); histology; combination of ALP+histology; and bilirubin. Of these, histology, ALP, and TE came out as the most promising. However, the expert panel concluded that no biomarker currently exceeds level 3 validation. Combining multiple endpoints is advisable. Conclusion: At present, there are insufficient data to support level 2 validation for any surrogate endpoint in PSC. Concerted efforts by all stakeholders are highly needed. Novel, promising noninvasive biomarkers are under study and should be incorporated as exploratory endpoints in clinical trials. (Hepatology 2016;63:1357–1367)Keywords
This publication has 57 references indexed in Scilit:
- Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitisDigestive and Liver Disease, 2011
- Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver diseaseGut, 2010
- Validation of a cholangiographic prognostic model in primary sclerosing cholangitisEndoscopy, 2010
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisHepatology, 2009
- Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot studyEuropean Journal of Gastroenterology & Hepatology, 2008
- Tacrolimus for the treatment of primary sclerosing cholangitisLiver International, 2007
- Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily dosesJournal of Hepatology, 1998
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis.Journal of Clinical Pathology, 1995
- Complications following percutaneous liver biopsyJournal of Hepatology, 1986